By September 15, 2026: Billing and clinical teams must identify all active MO HealthNet participants currently prescribed non-preferred biosimilars (Avsola, Idacio, Remicade, Renflexis, Zymfentra for Infliximab; Abrilada, Idacio, Yuflyma, Cyltezo, Simlandi, Amjevita, Cyltezo, Hulio, Humira, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry for Adalimumab; Imuldosa, Otulfi, Selarsdi, Starjemza, Stelara, Steqeyma, Ustekinumab, Yesinteka for Ustekinumab). Coordinate with prescribers and pharmacy providers to transition patients to preferred agents before October 1, 2026. Update billing system edits to enforce mandatory product switching to preferred biosimilars on or after October 1. Existing clinical prior authorizations will remain valid without requiring new PA submissions, but claims will be rejected at the fiscal edit level if non-preferred agents are billed after the effective date unless an explicit override is obtained. Pharmacy team should proactively contact prescribers for patients on non-preferred agents to request override requests if clinically necessary. Document all override approvals in the system to prevent claim denials.